| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_698e4d3e0941674667799fa83b45d988
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a808bb4bd836105cb0f42268ac6cc8a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10cbc9de20fbfa5d4174759fb72d9fd7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate |
2009-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36083814ce74480d71ce64ff30968959
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b563abdb949ac87e86802630b1d20a48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ad1e0f4e0226719125e38f32ae4d48d |
| publicationDate |
2011-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011123609-A1 |
| titleOfInvention |
Multiple unit dosage form of niacin |
| abstract |
A multiple unit dosage form useful for treating or preventing hyperlipidemia and/or atherosclerosis, wherein multiple unit dosage form comprise of a therapeutically effective amount of niacin or its derivatives and one or more control releasing agent(s) and pharmaceutically acceptable excipients, weight percentages are based upon the total weight of the dosage form. The multiple unit dosage form may comprise of optionally other antihyperlipidemic agent, more preferably HMG CoA reductase inhibitor. The most preferable dosage form is capsule. Further a kit comprising one or more capsules co-packaged to provide multiple unit dosage form of niacin or its derivatives in combination with HMG CoA reductase inhibitor is disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014220123-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10456389-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017140902-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11504330-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11311570-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11622938-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11234935-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014200347-A1 |
| priorityDate |
2008-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |